Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Venetoclax is named as an intervention in 126 current clinical trials in our China, USA, UK, Ireland and India registers. 77 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Institute of Hematology & Blood Diseases Hospital, China (15). The most-studied condition is Acute Myeloid Leukemia.

Venetoclax also has an approved-drug profile on this site (FDA label data): Venclexta (Venetoclax) →

Trials by status

Recruiting7761%
Not yet open76%
Active, closed4133%
By invitation11%

Trials by phase

Phase 24133%
Phase 32721%
Phase 1/22217%
Not applicable1210%
Phase 1119%
Phase 2/376%
Phase 443%
Observational22%

Clinical trials of Venetoclax

126 trials

Study	Phase	Status	Lead sponsor	Registers
RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR NCT06571825 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 4	Recruiting	He Huang	China
Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India NCT07044687 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 4	Recruiting	AbbVie	India
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). NCT05947851 · ClinicalTrials.gov ↗ · Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) NCT06428019 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia	Phase 3	Recruiting	AbbVie	UK, USA, China
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment NCT06496308 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL)	Phase 3	Recruiting	Ruijin Hospital	China
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors NCT06846671 · ClinicalTrials.gov ↗ · CLL, Chronic Lymphocytic Leukemia	Phase 3	Recruiting	BeOne Medicines	UK, USA
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) NCT06852222 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, China
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) NCT06943872 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Recruiting	BeOne Medicines	Ireland, UK, USA, China
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia NCT06990321 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Elderly	Phase 3	Recruiting	Yehui Tan	China
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML NCT07007312 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 3	Recruiting	Kura Oncology, Inc.	UK, USA
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients NCT07132684 · ClinicalTrials.gov ↗ · AML, Adult	Phase 3	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia NCT07277231 · Chronic Lymphocytic Leukemia	Phase 3	Recruiting	BeOne Medicines	UK, USA, China
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial NCT07396480 · ClinicalTrials.gov ↗ · Venentoclax, Myeloid Malignancies, Conditioning	Phase 3	Recruiting	First Affiliated Hospital of Zhejiang University	China
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia NCT07514936 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients	Phase 3	Recruiting	Chinese PLA General Hospital	China
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) NCT04256317 · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm	Phase 2/3	Recruiting	Taiho Oncology, Inc.	UK, USA
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission NCT05404906 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML) in Remission	Phase 2/3	Recruiting	The First Affiliated Hospital of Soochow University	China
VA vs DA for Newly Diagnosed Hig-risk AML NCT05939180 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2/3	Recruiting	The First Affiliated Hospital of Soochow University	China
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation NCT06972641 · ClinicalTrials.gov ↗ · AML, MDS	Phase 2/3	Recruiting	Ruijin Hospital	China
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia NCT07255872 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) NCT07581002 · Acute Myeloid Leukemia	Phase 2/3	Recruiting	AbbVie	USA, China
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) NCT04895436 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL)	Phase 2	Recruiting	AbbVie	UK, USA
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia NCT05566054 · ClinicalTrials.gov ↗ · Acute Monocytic Leukemia, Newly Diagnosed	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia NCT05660473 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia NCT05736965 · ClinicalTrials.gov ↗ · AML, Adult	Phase 2	Recruiting	Shanghai Tong Ren Hospital	China
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results NCT05736978 · ClinicalTrials.gov ↗ · AML, MRD	Phase 2	Recruiting	Shanghai Tong Ren Hospital	China
Venetoclax Combined With Azactidine in the Treatment of ALAL NCT05901974 · ClinicalTrials.gov ↗ · Acute Leukemia of Ambiguous Lineage	Phase 2	Recruiting	Sheng-Li Xue, MD	China
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia NCT06084819 · ClinicalTrials.gov ↗ · Relapsed/Refractory Acute Myeloid Leukemia	Phase 2	Recruiting	Chinese PLA General Hospital	China
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma NCT06115135 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory	Phase 2	Recruiting	Oncotherapeutics	USA
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML NCT06221683 · ClinicalTrials.gov ↗ · AML, Childhood, Acute Myeloid Leukemia	Phase 2	Recruiting	Children's Hospital of Soochow University	China
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL NCT06387121 · ClinicalTrials.gov ↗ · Precursor Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT NCT06447090 · ClinicalTrials.gov ↗ · Relapse Acute Myeloid Leukemia	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML NCT06451861 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Guangdong Provincial People's Hospital	China
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma NCT06471738 · ClinicalTrials.gov ↗ · Ann Arbor Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma	Phase 2	Recruiting	Chinese PLA General Hospital	China
Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL NCT06554626 · ClinicalTrials.gov ↗ · Precursor B-Cell Lymphoblastic Leukemia	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML NCT06621199 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML NCT06635681 · ClinicalTrials.gov ↗ · AML (Acute Myelogenous Leukemia)	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
VHAG in Treating R/R T-ALL/LBL NCT06742463 · ClinicalTrials.gov ↗ · Acute T Lymphpblastic Leukemia/Lymphoma	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients NCT06928376 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, First Line Therapy	Phase 2	Recruiting	Chinese PLA General Hospital	China
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy NCT06958705 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease NCT07023588 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 2	Recruiting	Yehui Tan	China
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab NCT07024706 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)	Phase 2	Recruiting	AstraZeneca	Ireland, USA
Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes NCT07047183 · ClinicalTrials.gov ↗ · Myelodysplastic Neoplasms, Transplantation	Phase 2	Recruiting	Yehui Tan	China
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML NCT07078591 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Beijing 302 Hospital	China
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) NCT07154264 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	Phase 2	Recruiting	Dizal Pharmaceuticals	China
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients NCT07159620 · ClinicalTrials.gov ↗ · Adult T-cell Leukemia/Lymphoma	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) NCT07719556 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL)	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia NCT07743112 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	Maxinovel Pty., Ltd.	China
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT03850574 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML	Phase 1/2	Recruiting	Aptose Biosciences Inc.	USA
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies NCT04068597 · Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma	Phase 1/2	Recruiting	CellCentric Ltd.	UK, USA
Study to Evaluate the Safety and Tolerability of EP0042 NCT04581512 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes	Phase 1/2	Recruiting	Ellipses Pharma	UK
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML NCT04588922 · Hematologic Malignancies	Phase 1/2	Recruiting	Sellas Life Sciences Group	USA, China
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) NCT04988555 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma	Phase 1/2	Recruiting	Sumitomo Pharma America, Inc.	UK, USA
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT05211570 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndrome Acute Myeloid Leukemia	Phase 1/2	Recruiting	AB Science	USA
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05745714 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	Phase 1/2	Recruiting	Princess Maxima Center for Pediatric Oncology	Ireland
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05751044 · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	Phase 1/2	Recruiting	Princess Maxima Center for Pediatric Oncology	Ireland
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia NCT06382168 · Leukemia, Myeloid, Acute	Phase 1/2	Recruiting	Delta-Fly Pharma, Inc.	USA
VA Conditioning Regimen Allo-HSCT for Elderly Higher-risk MDS NCT06471946 · ClinicalTrials.gov ↗ · Higher-risk Myelodysplastic Syndromes	Phase 1/2	Recruiting	Navy General Hospital, Beijing	China
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation NCT06561880 · ClinicalTrials.gov ↗ · FLT3 Gene Mutation, AML	Phase 1/2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML NCT06757855 · ClinicalTrials.gov ↗ · CML,Blast Phase	Phase 1/2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML NCT07451912 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML	Phase 1/2	Recruiting	The First Affiliated Hospital of Soochow University	China
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NCT07520006 · ClinicalTrials.gov ↗ · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 1/2	Recruiting	Nurix Therapeutics, Inc.	USA
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT05091424 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Phase 1	Recruiting	Hoffmann-La Roche	UK, USA, China
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184 · Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML	Phase 1	Recruiting	Kura Oncology, Inc.	USA
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT06419634 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndrome	Phase 1	Recruiting	Bristol-Myers Squibb	USA
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome NCT06501196 · ClinicalTrials.gov ↗ · Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute	Phase 1	Recruiting	BlossomHill Therapeutics	USA
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML NCT06634394 · Acute Myeloid Leukemia (AML)	Phase 1	Recruiting	Aptevo Therapeutics	USA
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP NCT06390306 · ClinicalTrials.gov ↗ · Chronic Myeloid Leukemia	Observational	Recruiting	Peking University People's Hospital	China
Optimize First-line Treatment for AL Amyloidosis With t (11; 14) NCT06192979 · ClinicalTrials.gov ↗ · Amyloidosis; Systemic, AL Amyloidosis	Not applicable	Recruiting	Jin Lu, MD	China
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia NCT06386302 · ClinicalTrials.gov ↗ · AML, Acute Myeloid Leukemia	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL NCT06481228 · ClinicalTrials.gov ↗ · Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL NCT06481241 · ClinicalTrials.gov ↗ · Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy NCT06643962 · ClinicalTrials.gov ↗ · Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute	Not applicable	Recruiting	Affiliated Hospital of Nantong University	China
MRD-positive AML Clinical Study NCT07131059 · ClinicalTrials.gov ↗ · AML, Adult	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study) NCT07183878 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes	Not applicable	Recruiting	First Affiliated Hospital of Zhejiang University	China
ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL NCT07454226 · ClinicalTrials.gov ↗ · Ph-Like, Acute Lymphoblastic Leukemia	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML NCT07490288 · ClinicalTrials.gov ↗ · AML	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL NCT07493161 · ClinicalTrials.gov ↗ · Ph+ ALL	Not applicable	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML NCT06763666 · ClinicalTrials.gov ↗ · Relapsed/Refractory AML	Phase 4	Not yet open	Nanfang Hospital, Southern Medical University	China
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML NCT07486479 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 3	Not yet open	The First Affiliated Hospital of Soochow University	China
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT NCT06765928 · ClinicalTrials.gov ↗ · MDS, AML, Adult	Phase 2	Not yet open	Ruijin Hospital	China
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia NCT06387420 · ClinicalTrials.gov ↗ · ACUTE MYELOID LEUKEMIA; AML	Phase 1/2	Not yet open	Akeso	China
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia NCT07486726 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)	Phase 1/2	Not yet open	Shanghai Jiao Tong University School of Medicine	China
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients NCT07722767 · AML (Acute Myeloid Leukemia)	Phase 1	Not yet open	Cullinan Therapeutics Inc.	USA
Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants With Acute Myeloid Leukemia NCT06841952 · ClinicalTrials.gov ↗ · AML, Adult	Not applicable	Not yet open	The First Affiliated Hospital of Soochow University	China
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients NCT06544109 · ClinicalTrials.gov ↗ · Acute Promyelocytic Leukemia	Phase 2/3	By invitation	The First Affiliated Hospital of Soochow University	China
Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China NCT05144243 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 4	Active, closed	AbbVie	China
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy NCT02993523 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 3	Active, closed	AbbVie	USA, China
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL NCT03336333 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Active, closed	BeiGene	UK, USA, China
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) NCT03462719 · ClinicalTrials.gov ↗ · Leukemia, Lymphocytic, Chronic, B-Cell	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. NCT03539744 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 3	Active, closed	AbbVie	UK, USA, China
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study NCT03768063 · ClinicalTrials.gov ↗ · Cancer	Phase 3	Active, closed	Hoffmann-La Roche	USA
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL NCT03836261 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia	Phase 3	Active, closed	Acerta Pharma BV	UK, USA, China
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial NCT03844048 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma	Phase 3	Active, closed	AbbVie	Ireland, UK, USA, China
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 NCT04229979 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 3	Active, closed	Sellas Life Sciences Group	USA, India
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome NCT04401748 · ClinicalTrials.gov ↗ · Myelodysplastic Syndrome (MDS)	Phase 3	Active, closed	AbbVie	UK, USA, China
Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) NCT04608318 · ClinicalTrials.gov ↗ · Chronic Lymphoid Leukemia	Phase 3	Active, closed	German CLL Study Group	Ireland
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) NCT04965493 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Phase 3	Active, closed	Loxo Oncology, Inc.	Ireland, UK, USA, China
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma NCT05057494 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Phase 3	Active, closed	AstraZeneca	USA
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML NCT05177731 · ClinicalTrials.gov ↗ · AML, Adult, Chemotherapy Effect	Phase 3	Active, closed	Chen Suning	China
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) NCT06073821 · ClinicalTrials.gov ↗ · CLL	Phase 3	Active, closed	BeOne Medicines	UK, USA, China
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) NCT02899052 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	AbbVie	USA
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma NCT02966756 · ClinicalTrials.gov ↗ · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)	Phase 2	Active, closed	AbbVie	China
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma NCT03314181 · ClinicalTrials.gov ↗ · Multiple Myeloma	Phase 2	Active, closed	AbbVie	USA
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. NCT05201066 · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic	Phase 2	Active, closed	Novartis Pharmaceuticals	USA, China
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma NCT05951959 · Mantle Cell Lymphoma (MCL)	Phase 2	Active, closed	AstraZeneca	UK, USA
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia NCT05963074 · ClinicalTrials.gov ↗ · Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma	Phase 2	Active, closed	Janssen Research & Development, LLC	USA
Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14) NCT05996406 · ClinicalTrials.gov ↗ · Light Chain (AL) Amyloidosis, CCND1 Translocation, Venetoclax	Phase 2	Active, closed	Peking Union Medical College Hospital	China
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy NCT06384261 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute	Phase 2	Active, closed	OncoVerity, Inc.	USA
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML NCT06429098 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Active, closed	The First Affiliated Hospital of Soochow University	China
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy NCT06456463 · Acute Myeloid Leukemia	Phase 2	Active, closed	Stemline Therapeutics, Inc.	USA
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period NCT06524375 · Chronic Lymphocytic Leukemia	Phase 2	Active, closed	Genentech, Inc.	USA
Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) NCT06629818 · ClinicalTrials.gov ↗ · Light Chain (AL) Amyloidosis	Phase 2	Active, closed	Peking Union Medical College Hospital	China
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML NCT06744556 · ClinicalTrials.gov ↗ · AML	Phase 2	Active, closed	Institute of Hematology & Blood Diseases Hospital, China	China
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) NCT03331198 · ClinicalTrials.gov ↗ · Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic	Phase 1/2	Active, closed	Juno Therapeutics, a Subsidiary of Celgene	USA
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia NCT04086264 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 1/2	Active, closed	AbbVie	UK, USA
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome NCT04623541 · ClinicalTrials.gov ↗ · Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome	Phase 1/2	Active, closed	Genmab	USA
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) NCT04657081 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 1/2	Active, closed	Taiho Oncology, Inc.	USA
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies NCT05428969 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes	Phase 1/2	Active, closed	Faron Pharmaceuticals Ltd	UK, USA
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia NCT05520567 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia	Phase 1/2	Active, closed	Astellas Pharma Global Development, Inc.	USA
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia NCT04150887 · Leukemia, Myeloid, Acute	Phase 1	Active, closed	OncoVerity, Inc.	USA
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies NCT04227847 · ClinicalTrials.gov ↗ · Myelodysplastic Syndrome, Acute Myeloid Leukemia	Phase 1	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations NCT04603001 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)	Phase 1	Active, closed	Eli Lilly and Company	USA, China
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies NCT05453903 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute	Phase 1	Active, closed	Janssen Research & Development, LLC	UK, USA
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies NCT05753501 · ClinicalTrials.gov ↗ · Hematologic Cancer	Phase 1	Active, closed	AbbVie	UK, USA
Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML NCT07318662 · ClinicalTrials.gov ↗ · MDS, CMML	Observational	Active, closed	Guangdong Provincial People's Hospital	China
Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia NCT07187505 · ClinicalTrials.gov ↗ · Acute Promyelocytic Leukemia (APL)	Not applicable	Active, closed	Anhui Medical University	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Venetoclax across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

3 single-substance products containing Venetoclax on the HPRA medicines list.

Venclyxto 10 mg film-coated tabletsAbbVie Deutschland GmbH & Co. KG · EU/1/16/1138/001-002
Venclyxto 100 mg film-coated tabletsAbbVie Deutschland GmbH & Co. KG · EU/1/16/1138/005-007
Venclyxto 50 mg film-coated tabletsAbbVie Deutschland GmbH & Co. KG · EU/1/16/1138/003-004

All 3 Irish products →

Supply shortages

No entry for Venetoclax in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Venetoclax

112 conditions

Acute Myeloid Leukemia26 Acute Myeloid Leukemia (AML)11 Chronic Lymphocytic Leukemia10 Leukemia, Myeloid, Acute9 Multiple Myeloma6 Small Lymphocytic Lymphoma6 Myelodysplastic Syndromes6 AML, Adult6 AML6Leukemia, Lymphocytic, Chronic, B-Cell4Chronic Lymphocytic Leukemia (CLL)3Chronic Myelomonocytic Leukemia3

All 112 conditions

Condition (as registered)	Trials
Acute Myeloid Leukemia	26
Acute Myeloid Leukemia (AML)	11
Chronic Lymphocytic Leukemia	10
Leukemia, Myeloid, Acute	9
Multiple Myeloma	6
Small Lymphocytic Lymphoma	6
Myelodysplastic Syndromes	6
AML, Adult	6
AML	6
Leukemia, Lymphocytic, Chronic, B-Cell	4
Chronic Lymphocytic Leukemia (CLL)	3
Chronic Myelomonocytic Leukemia	3
Mantle Cell Lymphoma (MCL)	3
MDS	3
Acute Lymphoblastic Leukemia	2
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent	2
Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent	2
Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory	2
Small Lymphocytic Lymphoma (SLL)	2
Myelodysplastic Syndrome (MDS)	2
Relapsed/Refractory AML	2
CLL	2
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	2
Lymphoma, Small Lymphocytic	2
Refractory AML	2
Myelodysplastic Syndrome	2
Leukemia	2
Leukemia, Myeloid	2
Relapse Acute Myeloid Leukemia	2
Acute Lymphoblastic Leukemia, Adult	2
Light Chain (AL) Amyloidosis	2
Precursor Cell Lymphoblastic Leukemia-Lymphoma	2
Non-Hodgkin's Lymphoma	1
Chronic Lymphoid Leukemia	1
Acute Lymphoblastic Leukemia, in Relapse	1
Haematological Malignancy	1
Non Hodgkin Lymphoma	1
Myelodysplastic Syndrome/Neoplasm	1
Leukemia, Lymphocytic, Acute	1
Leukemia, Chronic Lymphocytic	1
Small-Cell Lymphoma	1
Hematologic Cancer	1
Hematologic Malignancies	1
Mixed Lineage Leukemia Gene Mutation	1
AML With Mutated NPM1	1
Multiple Myeloma in Relapse	1
Multiple Myeloma, Refractory	1
AML (Acute Myeloid Leukemia)	1
Leukemia, Myelomonocytic, Chronic	1
Chronic Myelomonocytic Leukemia (CMML)	1
Myeloproliferative Neoplasms (MPNs)	1
B-cell Lymphoma	1
Cancer	1
Preleukemia	1
FLT3-mutated Acute Myeloid Leukemia	1
Relapsed Adult AML	1
Myelodysplastic Syndrome With Excess Blasts-2	1
Acute Myeloid Leukemia Refractory	1
Acute Myeloid Leukemia, in Relapse	1
Myelodysplastic Syndrome Acute Myeloid Leukemia	1
Relapsed/Refractory Chronic Lymphocytic Leukemia	1
Richter's Syndrome	1
Treatment-naïve High Risk Chronic Lymphocytic Leukemia	1
CMML	1
High-Risk Acute Myeloid Leukemia	1
High-Risk Myelodysplastic Syndromes	1
FLT3 Gene Mutation	1
First Line Therapy	1
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	1
Amyloidosis; Systemic	1
AL Amyloidosis	1
Ann Arbor Stage II Follicular Lymphoma	1
Grade 1 Follicular Lymphoma	1
Ann Arbor Stage III Follicular Lymphoma	1
Ann Arbor Stage IV Follicular Lymphoma	1
Venentoclax	1
Myeloid Malignancies	1
Conditioning	1
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	1
MRD	1
Precursor B-Cell Lymphoblastic Leukemia	1
Philadelphia Positive Acute Lymphoblastic Leukemia	1
Ph-Like	1
Adult T-cell Leukemia/Lymphoma	1
Chemotherapy Effect	1
Ph+ ALL	1
Acute Leukemia of Ambiguous Lineage	1
Myelodysplastic Neoplasms	1
Transplantation	1
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)	1
Chronic Myeloid Leukemia	1
CCND1 Translocation	1
Venetoclax	1
CML,Blast Phase	1
Acute Promyelocytic Leukemia (APL)	1
Acute Monocytic Leukemia	1
Newly Diagnosed	1
Acute Myeloid Leukemia (AML) in Remission	1
Philadelphia Chromosome Negative ALL	1
CEBPA Mutation	1
Unfit, New-diagnosis AML	1
Relapsed/Refractory Acute Myeloid Leukemia	1
ACUTE MYELOID LEUKEMIA; AML	1
Acute Promyelocytic Leukemia	1
Refractory Acute Myeloid Leukemia (AML)	1
Higher-risk Myelodysplastic Syndromes	1
Newly Diagnosed Acute Myeloid Leukemia (AML)	1
Elderly Patients	1
AML, Childhood	1
Elderly	1
AML (Acute Myelogenous Leukemia)	1
Acute T Lymphpblastic Leukemia/Lymphoma	1

By country register

Register	Trials	Recruiting
Clinical trials in China	82	56
Clinical trials in USA	56	24
Clinical trials in UK	26	13
Clinical trials in Ireland	7	4
Clinical trials in India	2	1

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Venetoclax trials

How many clinical trials are testing Venetoclax?

126 current trials in our China, USA, UK, Ireland and India registers name Venetoclax (also registered as ABT-199) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Venetoclax trials recruiting patients?

Yes. 77 of the 126 trials are recruiting: 56 with sites in China, 24 with sites in USA, 13 with sites in UK, 4 with sites in Ireland and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Venetoclax clinical trials?

Institute of Hematology & Blood Diseases Hospital, China (15), AbbVie (14), The First Affiliated Hospital of Soochow University (9) and First Affiliated Hospital of Zhejiang University (5), among 62 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Venetoclax licensed in Ireland?

Yes. The HPRA medicines list includes 3 single-substance products containing Venetoclax, for example Venclyxto 10 mg film-coated tablets (AbbVie Deutschland GmbH & Co. KG). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Venetoclax shortage?

Not in the lists we track: Venetoclax has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Venetoclax works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Venetoclax works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Venetoclax (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Venetoclax clinical trials